View Older Stories View More Recent Stories

Sep 21, 2020 12:30PM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer
Sep 21, 2020 08:33AM Merck (MRK) Reports First-Line Treatment with KEYTRUDA (pembrolizumab) Doubled 5-Yr Survival Rate (31.9%) vs. Chemotherapy (16.3%) in Certain Patients w/ Metastatic NSCLC & PD-LI Turmors
Sep 21, 2020 08:25AM First-Line Treatment With Merck’s KEYTRUDA® (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients With Metastatic Non-Small Cell Lung Cancer Whose
Sep 21, 2020 06:47AM AstraZeneca (AZN) and Merck (MRK) Announce LYNPARZA Receives Positive Opinion from EU CHMP for Treatment of BRCA1/2 mCRPC
Sep 21, 2020 06:45AM LYNPARZA® (olaparib) Recommended for Approval in EU by CHMP as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer
Sep 21, 2020 06:45AM LYNPARZA® (olaparib) Receives Positive Opinion from EU CHMP for Treatment of BRCA1/2 Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Sep 20, 2020 12:30PM LYNPARZA Reduced Risk of Death by 31% vs. Enzalutamide or Abiraterone for Men with BRCA1/2 or ATM-Mutated Metastatic Castration Resistant Prostate Cancer Who Progressed Following Enzalutamide or Abira
Sep 20, 2020 12:30PM LYNPARZA® (olaparib) Reduced the Risk of Death by 31% in BRCA1/2 or ATM-mutated Metastatic Castration-Resistant Prostate Cancer in Phase III Profound Trial
Sep 20, 2020 10:20AM Merck Presents Promising New Data for Three Investigational Medicines From Diverse and Expansive Oncology Pipeline at ESMO Virtual Congress 2020
Sep 20, 2020 08:25AM Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020
Sep 19, 2020 10:20AM Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma
Sep 18, 2020 06:46AM AstraZeneca (AZN), Merck (MRK) Report LYNPARZA Improved Median PFS to Over Four and a Half Years Compared to 13.8 Months with Placebo for Patients with BRCA-Mutated Advanced Ovarian Cancer
Sep 18, 2020 06:45AM LYNPARZA® (olaparib) Improved Median Progression-Free Survival to Over Four and a Half Years Compared to 13.8 Months with Placebo for Patients with BRCA-Mutated Advanced Ovarian Cancer
Sep 18, 2020 06:02AM Pfizer (PFE), Merck (MRK) Biopharmaceutical Business, EMD Serono, Reports Publication of BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results
Sep 18, 2020 03:00AM BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine
Sep 16, 2020 06:45AM Merck to Hold Investor Briefing Following ESMO Virtual Congress 2020
Sep 15, 2020 06:45AM Merck to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
Sep 14, 2020 06:45AM Seattle Genetics (SGEN) and Merck (MRK) Announce Two Strategic Oncology Collaborations; Merck to Invest $1B
Sep 14, 2020 06:45AM Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations
Sep 10, 2020 06:45AM Merck to Present at the Morgan Stanley 18th Annual Virtual Global Healthcare Conference
Sep 9, 2020 09:00AM MilliporeSigma Announces $65 Million Antibody-Drug Conjugate Manufacturing Expansion
Sep 9, 2020 09:00AM /C O R R E C T I O N -- MilliporeSigma/
Sep 9, 2020 06:46AM Merck (MRK) Announces Positive Topline Results from Two Phase 3 Adult Studies Evaluating V114, Investigational 15-valent Pneumococcal Conjugate Vaccine, Including Pivotal Trial
Sep 9, 2020 06:45AM Merck Announces Positive Topline Results from Two Phase 3 Adult Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, Including Pivotal Trial
Sep 8, 2020 06:48AM Merck's (MRK) Gefapixant Significantly Decreased Cough Frequency Compared to Placebo at Week 12 and 24 in Patients with Refractory or Unexplained Chronic Cough
Sep 8, 2020 06:45AM Merck’s Gefapixant (45 mg Twice Daily) Significantly Decreased Cough Frequency Compared to Placebo at Week 12 and 24 in Patients with Refractory or Unexplained Chronic Cough
Sep 8, 2020 06:31AM Vaccine makers announce pledge, outlining united commitment to uphold integrity of scientific process
Sep 8, 2020 06:31AM Biopharma Leaders Unite to Stand With Science
Sep 8, 2020 06:30AM Biopharma Leaders Unite to Stand with Science
Sep 8, 2020 06:30AM Biopharma Leaders Unite To Stand With Science
Sep 8, 2020 06:30AM Biopharma Leaders Unite to Stand with Science
Sep 8, 2020 06:30AM Biopharma Leaders Unite to Stand with Science
Sep 4, 2020 06:45AM Merck to Present at the Citi 15th Annual BioPharma Virtual Conference
Sep 2, 2020 06:46AM Merck (MRK) Says New Scientific Data at the ESMO Virtual Congress 2020 Reflect its Commitment to Advancing Cancer Research and Care
Sep 2, 2020 06:45AM New Scientific Data at the ESMO Virtual Congress 2020 Reflect Merck’s Commitment to Advancing Cancer Research and Care
Aug 24, 2020 06:45AM Merck's (MRK) KEYTRUDA Receives Two New Approvals in Japan
Aug 24, 2020 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan
Aug 19, 2020 06:58AM Merck's (MRK) KEYTRUDA in Combination With Chemotherapy Significantly Improved OS and PFS Compared With Chemotherapy in Locally Advanced or First-Line Metastatic Esophageal Cancer
Aug 19, 2020 06:45AM Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With Chemotherapy in Locally Advanced or First-Line
Aug 5, 2020 07:00AM Merck Animal Health Completes Acquisition of IdentiGEN
Aug 4, 2020 05:00AM Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for Nonalcoholic Steatohepatitis (NASH)
Aug 3, 2020 06:40AM Merck (MRK) Animal Health Completes Acquisition of Worldwide Rights to VECOXAN Brand of Parasiticides for Ruminant Portfolio
Aug 3, 2020 06:30AM Merck Animal Health Completes Acquisition of Worldwide Rights to VECOXAN® Brand of Parasiticides for Ruminant Portfolio
Jul 31, 2020 06:45AM  Merck Announces Second-Quarter 2020 Financial Results
Jul 30, 2020 07:30AM Merck (MRK) Announces Two US Regulatory Milestones for KEYTRUDA in Triple-Negative Breast Cancer
Jul 30, 2020 06:45AM Merck Announces Two US Regulatory Milestones for KEYTRUDA® (pembrolizumab) in Triple-Negative Breast Cancer (TNBC)
Jul 29, 2020 06:46AM Merck (MRK) Announces FDA Grants Breakthrough Therapy Designation to Novel HIF-2α Inhibitor MK-6482 for Treatment of Certain Patients With VHL- Associated RCC
Jul 29, 2020 06:45AM FDA Grants Breakthrough Therapy Designation to Merck’s Novel HIF-2α Inhibitor MK-6482 for Treatment of Certain Patients With Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma
Jul 28, 2020 01:30PM Merck Announces Fourth-Quarter 2020 Dividend
Jul 20, 2020 01:23PM Factbox: More companies join Facebook ad boycott bandwagon
View More Recent Stories View Older Stories